Skip to content
Review Open access

Autonomous AI-driven point-of-care screening for diabetic retinopathy compared to reading center multi-expert clinical review: results from three prospective controlled pivotal validation studies with AEYE-DS in over 1,200 patients

Aug 2026 · Frontiers in Digital Health · Vol 8 · 0 citations · 22 references
Medicine

Abstract

Purpose Diabetic retinopathy (DR) remains the leading cause of blindness among working-age adults and requires regular screening to detect progression among the growing global diabetic population. This study evaluated the performance of AEYE-DS, an autonomous artificial intelligence (AI) system designed for high-throughput, point-of-care analysis of retinal images, in detecting more-than-mild diabetic retinopathy (mtmDR) during routine screening of patients with diabetes who had not previously been diagnosed with DR. Principal results AEYE-DS was tested across three prospective clinical studies using two FDA-cleared non-mydriatic retinal cameras: the handheld Aurora and the desktop Topcon NW400. The algorithm autonomously analyzed retinal images and determined mtmDR presence. Diagnostic outcomes were compared to a reference standard based on the Early Treatment for Diabetic Retinopathy Study (ETDRS) severity grading performed by multi-expert review at an independent reading center. Sensitivity and specificity were 93% and 91% in AEYE-1 (95% CI: 83%–97% and 88%–94%), 92% and 94% in AEYE-2 (95% CI: 79%–97% and 90%–96%), and 93% and 89% in AEYE-3 (95% CI: 80%–97% and 85%–92%). Imageability was >99% in all studies. Intra-operator repeatability exceeded 99% for both devices. Between-operator reproducibility was 98% for the desktop camera and 95% for the handheld device, while between-device reproducibility reached 99% and 97%, respectively. Conclusions AEYE-DS demonstrated high diagnostic accuracy, imageability, reliability, and reproducibility across different operators and devices in non-mydriatic settings. Findings support autonomous AI system use for scalable, point-of-care DR screening, potentially expanding access, streamlining workflows, and reducing the global burden of diabetic eye disease.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.